ArticleChinese medicine2025
Effect of age on the efficacy and safety of Panax notoginseng saponins in acute ischemic stroke: a prespecified secondary analysis of the PANDA study.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunctive traditional Chinese medicine for ischemic stroke: a systematic review with structured narrative synthesis and GRADE assessment of randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Effect of diabetes on the efficacy and safety ofJournal of ginseng research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe therapeutic utility of Panax notoginseng saponins (Xuesaitong soft capsules) for patients with acute ischemic stroke (AIS) was previously demonstrated through the PANax notoginseng Saponins Treatment of aDults with ischemic stroke in ChinA (PANDA) trial, revealing significant gains in functional independence compared to placebo. However, the related variation of older age accepted as the predictors of poor outcome, in response to Panax notoginseng saponins remains unexplored.
methodsWe conducted a prespecified analysis of the PANDA trial to evaluate the effect of age on the efficacy and safety of Xuesaitong soft capsules. A multivariable logistic and Cox regression analysis with an interaction term was used to determine whether age (< 65 years vs. ≥ 65 years) affected the treatment effect. The primary outcome of this study was functional independence at the 3-month follow-up, as indicated by a modified Rankin Scale score (mRS) ranging from 0 to 2.
resultsBetween July 1 th, 2018, and June 30 th, 2020, a total of 3072 patients were recruited from 67 medical centers in China. Of these, 2966 patients were incorporated into the intention-to-treat (ITT) analysis and subsequently categorized into two age-based subgroups: (1) 1788 patients (60.28%) aged less than 65 years and (2) 1178 patients (39.72%) aged 65 years or older. Age significantly influenced the proportion of AIS patients attaining functional independence within three months [aged ≥ 65 years, adjusted odds ratio (aOR): 3.15, 95% CI: 2.13-4.67, P < 0.0001; aged < 65 years, aOR: 1.84, 95% CI: 1.33-2.54, P = 0.0002; P for interaction = 0.027]. Notably, a significant interaction was detected between age categories and treatment, with a greater likelihood of achieving functional independence among AIS patients aged ≥ 65 years. Regarding the primary safety outcome, which measured the rate of serious adverse events (SAEs) at 3 months, no significant difference was detected between the treatment and placebo groups across both age categories (aged ≥ 65 years, aOR: 0.32, 95% CI: 0.06-1.69, P = 0.181; aged < 65 years, aOR: 1.76, 95% CI: 0.41-7.47, P = 0.444; P for interaction = 0.132).
conclusionsThis prespecified secondary analysis suggests that AIS patients can potentially benefit from Xuesaitong treatment in achieving functional independence, irrespective of age. Furthermore, older individuals may experience more substantial clinical benefits from Xuesaitong soft capsules for AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.